FREQ News and Press, Frequency Therapeutics Inc. From 09/13/20

Evidence of Durable Hearing Improvements in Follow-Up with Patients from Phase 1/2 Study; Speech Intelligibility and Audibility Sustained for Up to 21 Months After Initial Dosing Data Highlighted at the 2020 American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Company management will be presenting at the following ...

Frequency Therapeutics (NASDAQ: FREQ ) : Q2 GAAP EPS of -$0.19 beats by $0.03 . Revenue of $8.52M beats by $2.38M . Press Release More news on: Frequency Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

Expects to Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss by Early Q4 2020; Study Readout Anticipated in Q2 2021 Recently Announced Clinical Data Show FX-322 Delivery to the Cochlea and Preliminary Evidence of a Durable Clinical Benefit; Plans New Studie...

Frequency Therapeutics (NASDAQ: FREQ ) to sell ~2.4M shares at $18/share via private placement, for gross proceeds of $42.3M. More news on: Frequency Therapeutics, Inc., Healthcare stocks news, , Read more ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has agreed to sell 2,350,108 shares of its common st...

The following slide deck was published by Frequency Therapeutics, Inc. in conjunction with this Read more ...

Frequency Therapeutics ( FREQ ), which is a biotechnology company that focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, most recently reported its first-quarter results and provided top line data from its exploratory ...

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present ...

Frequency Therapeutics (NASDAQ: FREQ ): Q1 GAAP EPS of -$0.16 beats by $0.08 . More news on: Frequency Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...